Leila Alland Sells 18,065 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Leila Alland sold 18,065 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $91,950.85. Following the completion of the transaction, the director owned 173,614 shares of the company’s stock, valued at $883,695.26. This represents a 9.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Abeona Therapeutics Stock Up 1.9%

ABEO stock opened at $5.27 on Wednesday. The firm’s 50-day moving average is $5.17 and its two-hundred day moving average is $5.58. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $285.58 million, a price-to-earnings ratio of 4.28 and a beta of 1.18. Abeona Therapeutics Inc. has a 52 week low of $3.93 and a 52 week high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. On average, analysts forecast that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. purchased a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at approximately $25,000. Legal & General Group Plc purchased a new stake in shares of Abeona Therapeutics in the second quarter valued at $27,000. Russell Investments Group Ltd. purchased a new stake in shares of Abeona Therapeutics in the third quarter valued at $37,000. Legato Capital Management LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter worth $57,000. Finally, SG Americas Securities LLC purchased a new position in shares of Abeona Therapeutics during the fourth quarter valued at $57,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics News Summary

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: Institutional buying: multiple funds disclosed new or larger stakes in ABEO (AIGH Capital Management, Aberdeen Group among others), signaling professional investor interest that can support the share price. MarketBeat Institutional Trading
• Positive Sentiment: Recent quarter topped expectations: Abeona reported -$0.10 EPS vs. Street -$0.27 on Nov. 12, which is a positive fundamental surprise for a clinical-stage biotech that can lift sentiment. Earnings Recap
• Positive Sentiment: Balance sheet and liquidity appear strong (high current and quick ratios, low debt-to-equity), reducing near-term financing risk for clinical programs — a positive for risk-sensitive investors. Financials
• Neutral Sentiment: Analyst landscape is mixed but tilted positive: several buy ratings and an average target materially above the current price (MarketBeat cites an average target near $20), though opinions vary. Analyst Notes
• Neutral Sentiment: Inclusion on retail/investor lists: Abeona appeared in a Yahoo Finance roundup of “Insider-Favored Growth Companies To Watch,” which can boost visibility but is not a fundamental catalyst by itself. Yahoo Article
• Neutral Sentiment: Short-interest notes show effectively zero reported short interest and a 0.0 days-to-cover figure in recent reports — likely a reporting artifact and not meaningful market pressure at present.
• Negative Sentiment: Insider selling: several directors sold shares on Feb. 2 (Leila Alland sold 18,065 shares; Eric Crombez sold 16,284 shares; Mark Alvino sold 2,000 shares). Large or clustered director sales can weigh on sentiment even if they may be liquidity-driven. Recent filings: SEC/InsiderTrades disclosures. InsiderTrades Article SEC Filing

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Monday, October 13th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Abeona Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.